에 대한 최신 뉴스 Veracyte (NASDAQ:VCYT) 주식

Veracyte

Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.

Equities

News

Markets

Tech

ETFs

ADPT

ARKG

ARKK

CDNA

PLTR

VCYT

월요일(13일) 캐시 우드가 이끄는 아크 인베스트는 팔란티어 테크놀로지스(NASDAQ:PLTR), 템퍼스 AI(NASDAQ:TEM), 케어Dx (NASDAQ:CDNA), 베라사이트(NASDAQ:VCYT), 어댑티브 바이오테크놀로지스 (NASDAQ:ADPT) 등 5개의 주요 기업에서 중요한 거래를 진행했다.

캐시 우드의 아크 인베스트, 팔란티어 주가 하락 속 추가 매도

Biotech

Health Care

BEAM

CRSP

NTLA

RXRX

TWST

아크 인베스트의 CEO인 캐시 우드는 인공지능, 유전자 염기서열(시퀀싱) 분석, 유전자 편집 기술의 교차점에서 전례 없는 잠재력을 발견하고 바이오 분야에 투자를 강화하고 있다.

캐시 우드, 바이오 분야에서 4천억 달러 기회 전망

Mid Cap

Movers

ADMA

Core Scientific, Inc. - Class A Common Stock

CORZ

LUMN

UPST

다음은 지난주 큰 폭의 상승세를 보인 7개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 루멘 테크놀로지스(NYSE:LUMN)의 주가는 회사가 2분기 매출 결과를 보고한 후 113.82% 급등했다. 여러 분석가가 주식의 목표 가격을 상향 조정했다.

루멘 테크 및 업스타트는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (8월 4일-8월 10일)

Veracyte Inc

7 analysts have expressed a variety of opinions on Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $41.14, a high estimate of $51.00, and a low estimate of $28.00. Observing a 9.91% increase, the current average has risen from the previous average price target of $37.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1738155639_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Veracyte is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$44.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$44.00</td>
<td>$37.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Veracyte. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Veracyte compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Veracyte's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Veracyte's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VCYT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Veracyte analyst ratings.</a>
<h2>Unveiling the Story Behind Veracyte</h2>
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.
<h3>Financial Insights: Veracyte</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Veracyte's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 28.58%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Veracyte's net margin is impressive, surpassing industry averages. With a net margin of 13.08%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Veracyte's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.31% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Veracyte's ROA excels beyond industry benchmarks, reaching 1.21%. This signifies efficient management of assets and strong financial health.
Debt Management: Veracyte's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Demystifying Veracyte: Insights From 7 Analyst Reviews

Needham analyst Mike Matson maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and raises the price target from $44 to $51.

Price Target

Needham Maintains Buy on Veracyte, Raises Price Target to $51

On Monday, Cathie Wood-led Ark Invest made significant trades in five major companies: Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), Tempus AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), CareDx Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), Veracyte Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>).
The PLTR Trade
Ark Invest&#8217;s Ark Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) fund sold 140,518 shares of Palantir. This move is significant, considering Ark Invest&#8217;s&nbsp;<a href="https://www.benzinga.com/25/01/42865484/cathie-woods-tuesday-double-dump-ark-invest-trims-both-palantir-and-bitcoin-etf-holdings">recent trend of offloading Palantir shares</a>.
The total value of this trade, based on the latest closing price of $64.98, is approximately $9.1 million.
This sale follows Ark&#8217;s disposal of shares worth roughly $15 million the previous week.
Palantir stock price has fallen more than 14% over the past month. In just the first two weeks of 2025, the stock has declined nearly 15%.
The TEM Trade
Ark Invest&#8217;s ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and ARKK funds made substantial purchases of Tempus AI Inc. shares. The ARKG fund bought 98,691 shares, while the ARKK fund purchased a whopping 280,192 shares.
Given the latest closing price of $32.34, the total value of these trades amounts to approximately $12.2 million.
This move comes amid TEM&#8217;s 13.81% drop on Monday.
Other Key Trades:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>ETF</td>
<td>Transaction</td>
<td>No. Of Shares</td>
<td>Closing price</td>
<td>Approx. Value</td>
</tr>
<tr>
<td>Veracyte Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>)</td>
<td>ARK Genomic Revolution</td>
<td>Sale</td>
<td>37,358</td>
<td>$42.78</td>
<td>$1.6 million</td>
</tr>
<tr>
<td>Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>)</td>
<td>ARK Genomic Revolution</td>
<td>Sale</td>
<td>76,522</td>
<td>$6.46</td>
<td>$494,332</td>
</tr>
<tr>
<td>CareDx Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>)</td>
<td>ARK Genomic Revolution</td>
<td>Sale</td>
<td>65,550</td>
<td>$25.07</td>
<td>$1.6 million</td>
</tr>
</tbody>
</table>
</figure>
Closing price as of Jan. 13, 2025
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42931941/mark-zuckerberg-critiques-culturally-neutered-companies-advocates-for-masculine-energy-as-meta-cuts-dei-programs-post-joe-rogan-appearance">Mark Zuckerberg Critiques &#8216;Culturally Neutered&#8217; Companies, Advocates For &#8216;Masculine Energy&#8217; As Meta Cuts DEI Programs Post-Joe Rogan Appearance</a></li>
</ul>
Image via Benzinga YouTube and Unsplash
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/Rounak-Jain" target="_blank" rel="noreferrer noopener">Rounak Jain</a>

Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025

9 analysts have expressed a variety of opinions on Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Veracyte, presenting an average target of $40.0, a high estimate of $46.00, and a low estimate of $28.00. Marking an increase of 10.68%, the current average surpasses the previous average price target of $36.14. 
<img src="https://www.benzinga.com/files/images/story/2024/1733414409_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Veracyte. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$44.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$44.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Lu Li</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$43.00</td>
<td>-</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Veracyte. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Veracyte compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Veracyte's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Veracyte's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VCYT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Veracyte analyst ratings.</a>
<h2>All You Need to Know About Veracyte</h2>
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.
<h3>Understanding the Numbers: Veracyte's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Veracyte's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 28.58%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 13.08%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.31%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Veracyte's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.21%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Veracyte's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 9 Analyst Ratings For Veracyte

Goldman Sachs analyst Matthew Sykes downgrades Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) from Buy to Neutral and lowers the price target from $38 to $37.

Downgrades

Goldman Sachs Downgrades Veracyte to Neutral, Lowers Price Target to $37

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
What Happened: Wood&#8217;s enthusiasm centers on what she describes as a transformative convergence of technologies that could revolutionize medical treatment and drug discovery. 
Speaking candidly about the sector, Wood highlighted the remarkable progress in genetic therapies, particularly in companies like Crispr Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), Intellia Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), and Beam Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>).
Her most striking example involves Crispr Therapeutics&#8217; recent breakthrough in sickle cell disease treatment. Wood noted, referencing how patients who previously required 12 to 20 annual blood transfusions might now be free from such interventions.
The strategy extends beyond treatment breakthroughs to drug development itself. Wood points to companies like Recursion Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) as leveraging artificial intelligence to dramatically reduce clinical trial failure rates and accelerate drug development timelines.
However, the market performance of these innovative companies tells a more nuanced story. Year-to-date, the stocks have experienced significant volatility: Crispr Therapeutics is down 25.36%, Intellia Therapeutics has dropped 52.21%, Beam Therapeutics declined 3.04%, and Recursion Pharmaceuticals fell 9.80%, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Which market sector excites <a href="https://twitter.com/CathieDWood?ref_src=twsrc%5Etfw">@CathieDWood</a> the most and why? In <a href="https://twitter.com/hashtag/askARK?src=hash&amp;ref_src=twsrc%5Etfw">#askARK</a>, she shares her growing enthusiasm for the biologics space. Have more questions for Cathie? Share them in the comments. <a href="https://t.co/WjilZChce6">pic.twitter.com/WjilZChce6</a>
&mdash; ARK Invest (@ARKInvest) <a href="https://twitter.com/ARKInvest/status/1861431767506268404?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/entertainment/24/11/42205763/disney-reaches-43m-settlement-in-gender-pay-discrimination-lawsuit-women-can-expect-equitable-treatment-moving-forward">Disney Reaches $43M Settlement In Gender Pay Discrimination Lawsuit: &#8216;Women Can Expect Equitable Treatment&#8217; Moving Forward</a>
Why It Matters: ARK&#8217;s commitment to this sector is evident through its Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>), which manages net assets of $1.179 billion. The fund&#8217;s performance reflects the sector&#8217;s volatility, with annual returns ranging from a high of 180.50% in 2020 to a low of -53.94% in 2022.
The ETF&#8217;s current top holdings underscore Wood&#8217;s strategic focus on innovative biological technologies. Twist Bioscience Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) leads the portfolio at 8.90%, followed by Crispr Therapeutics at 7.88% and Recursion Pharmaceuticals at 6.17%. Other significant investments include CareDx Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), Veracyte Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), and Adaptive Biotechnologies Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>), representing a diversified approach to genomic and biological innovation.
Wood&#8217;s vision suggests a potential $400 billion market opportunity in biologics over the next five years, driven by the unprecedented convergence of AI, sequencing technologies, and gene editing. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42202496/goldman-sachs-expects-major-selloffs-in-canadian-dollar-mexican-peso-says-trump-tariffs-threaten-usmca-agreement">Goldman Sachs Expects Major Selloffs In Canadian Dollar, Mexican Peso, Says Trump Tariffs Threaten USMCA Agreement</a></li>
</ul>
Image via Ark Invest
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Underweight and raises the price target from $26 to $28.

Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $28

Scotiabank analyst Sung Ji Nam maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Sector Outperform and raises the price target from $40 to $44.

Scotiabank Maintains Sector Outperform on Veracyte, Raises Price Target to $44

Goldman Sachs analyst Matthew Sykes maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and raises the price target from $34 to $38.

Goldman Sachs Maintains Buy on Veracyte, Raises Price Target to $38

WIIM

Veracyte shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance. Needham and UBS maintained Buy ratings and raised their respective price targets on the stock.

UBS analyst Lu Li maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and raises the price target from $43 to $46.

UBS Maintains Buy on Veracyte, Raises Price Target to $46

Needham analyst Mike Matson maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy and raises the price target from $37 to $44.

Needham Maintains Buy on Veracyte, Raises Price Target to $44

Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.03 by 1000 percent. The company reported quarterly sales of $115.860 million which beat the analyst consensus estimate of $109.812 million by 5.51 percent. This is a 28.58 percent increase over sales of $90.108 million the same period last year.

Earnings

Earnings Beats

Veracyte Q3 2024 Adj. EPS $0.33 Beats $0.03 Estimate, Sales $115.860M Beat $109.812M Estimate

Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) raises FY2024 sales outlook from $432.00 million-438.00 million to $442.00 million-445.00 million.

Guidance

Veracyte Raises FY2024 Sales Guidance from $432.00M-438.00M to $442.00M-445.00M  VS Est. 436.14M

Leerink Partners analyst Puneet Souda maintains Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Outperform and raises the price target from $35 to $40.

Leerink Partners Maintains Outperform on Veracyte, Raises Price Target to $40

UBS analyst Lu Li initiates coverage on Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy rating and announces Price Target of $43.

Initiation

UBS Initiates Coverage On Veracyte with Buy Rating, Announces Price Target of $43

Across the recent three months, 4 analysts have shared their insights on Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $33.5, a high estimate of $40.00, and a low estimate of $26.00. Witnessing a positive shift, the current average has risen by 27.23% from the previous average price target of $26.33.
<img src="https://www.benzinga.com/files/images/story/2024/1728576028_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Veracyte is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$37.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$26.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Veracyte. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Veracyte compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Veracyte's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Veracyte's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VCYT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Veracyte analyst ratings.</a>
<h2>About Veracyte</h2>
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.
<h3>Breaking Down Veracyte's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Veracyte showcased positive performance, achieving a revenue growth rate of 26.69% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Veracyte's net margin is impressive, surpassing industry averages. With a net margin of 5.01%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Veracyte's ROE excels beyond industry benchmarks, reaching 0.51%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Veracyte's ROA excels beyond industry benchmarks, reaching 0.47%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Veracyte: 4 Analysts Share Their Views

Guggenheim analyst Subbu Nambi initiates coverage on Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) with a Buy rating and announces Price Target of $40.

Guggenheim Initiates Coverage On Veracyte with Buy Rating, Announces Price Target of $40

Findings are from the prospective, multicenter VANDAAM trial
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.veracyte.com%2F&amp;esheet=54130421&amp;newsitemid=20241002846726&amp;lan=en-US&amp;anchor=Veracyte%2C+Inc&amp;index=1&amp;md5=34ebf73283d8ccb09db73586947cabed">Veracyte, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), a leading cancer diagnostics company, announced that new data from the multicenter, prospective <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT02723734&amp;esheet=54130421&amp;newsitemid=20241002846726&amp;lan=en-US&amp;anchor=VANDAAM+trial&amp;index=2&amp;md5=df7962e3c767658f465ed8d0a0feb6e7">VANDAAM trial</a> show that the Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer among African American men with early-stage disease. The findings confirm that the market-leading genomic test offers clinicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions for African American men, a population that is disproportionately impacted by the disease. The new data were shared today in an oral presentation at ASTRO 2024, the annual meeting of the American Society for Radiation Oncology, in Washington, D.C.
African American men are more than 70% as likely to be diagnosed with prostate cancer and more than twice as likely to die of the disease, compared to white men, according to the American Cancer Society.1 Despite this, few prospective studies have specifically sought to examine the disease at a genomic level in this population.

General

Veracyte Presents New Data Findings Are From The Prospective, Multicenter VANDAAM Trial, Show That Its Decipher Prostate Test Predicts Aggressive Prostate Cancer In African American Men At ASTRO 2024

<ul>
<li>Findings are from ancillary study of phase 3 STAMPEDE trial</li>
<li>Data support company&#39;s plan to expand Decipher Prostate test to patients with metastatic disease</li>
</ul>

Reported Sunday, Data Presented At ESMO 2024 Reveals Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit In Metastatic Prostate Cancer Patients

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on PepGen Inc. (PEPG – Research Report), Ligand Pharma ...

Analysts Are Bullish on Top Healthcare Stocks: PepGen Inc. (PEPG), Ligand Pharma (LGND)

Scotiabank raised the firm's price target on Veracyte (VCYT) to $44 from $40 and keeps an Outperform rating on the shares. The company's Q3 revenue...

Veracyte price target raised to $44 from $40 at Scotiabank

Veracyte (VCYT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Puneet Souda from Leeri...

Strategic Focus and Growth Potential Drive Buy Rating for Veracyte

ARKK's holdings ranked by SA Quant Grades

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Morgan Stanley, Comerica upgraded: Wall Street's top analyst calls

Tejas Savant, an analyst from Morgan Stanley, maintained the Sell rating on Veracyte (VCYT – Research Report). The associated price target is $28.0...

Sell Rating on Veracyte: Strong Performance Overshadowed by Limited Immediate Upside

Goldman Sachs downgraded Veracyte (VCYT) to Neutral from Buy with a price target of $37, down from $38. The firm says Veracyte has been one of the ...

Veracyte downgraded to Neutral from Buy at Goldman Sachs

Veracyte (VCYT – Research Report) received a Hold rating and price target from Goldman Sachs analyst Matthew Sykes today. The company's shares open...

Veracyte (VCYT) was downgraded to a Hold Rating at Goldman Sachs

Veracyte: Getting Frothy

Veracyte (VCYT) announced that 17 Decipher-focused abstracts will be presented at the 2025 ASCO Genitourinary Cancers Symposium, ASCO GU. The findi...

Veracyte announces 17 Decipher-focused abstracts at 2025 ASCO GU

ACHR

AKYA

AMZN

ARKF

ARKQ

ARKW

ARKX

BLUE

CERS

COIN

DKNG

EXAS

HOOD

ILMN

LGND

NTRA

PACB

PATH

PEPG

PINS

PRME

RBLX

REGN

ROKU

SBUX

SEDG

SHOP

SOFI

TSLA

TWLO

VERV

Press Releases

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

New Data Presented at ASTRO 2024 Show that Veracyte's Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

Veracyte to Participate in Upcoming Investor Conferences

Veracyte Announces Third Quarter 2024 Financial Results

Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

ADMA Biologics

Akero Therapeutics

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

Biohaven

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Denali Therapeutics

Amicus Therapeutics

ImmunityBio

Immunovant

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

PTC Therapeutics

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Zai Lab

Needham

Goldman Sachs

Morgan Stanley

Scotiabank

월요일(13일) 캐시 우드가 이끄는 아크 인베스트는 팔란티어 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), 템퍼스 AI(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), 케어Dx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), 베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), 어댑티브 바이오테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) 등 5개의 주요 기업에서 중요한 거래를 진행했다.
<h3>팔란티어 거래</h3>
아크 인베스트의 Ark Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)는 팔란티어 주식 140,518주를 매각했다. 이는 아크 인베스트가 최근에 팔란티어 주식을 처분하는 추세를 보인 것을 감안할 때 중요한 움직임이며, <a href="https://www.benzinga.com/25/01/42865484/cathie-woods-tuesday-double-dump-ark-invest-trims-both-palantir-and-bitcoin-etf-holdings">최근 경향</a>을 고려할 때 주목할 만하다.
최근 종가인 64.98달러를 기준으로 한 이번 거래의 총 가치는 약 910만 달러에 달한다. 이번 매각은 지난주 아크 인베스트가 약 1,500만 달러 상당의 팔란티어 주식을 처분한 데 이어 나타났다.
팔란티어 주가는 지난 한 달 동안 14.22% 하락했고, 올해 들어서는 14.77% 하락했다.
<h3>템퍼스 AI 거래</h3>
아크 인베스트의 ARK Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)와 ARKK 펀드는 템퍼스 AI 주식 상당량을 매입했다. ARKG 펀드는 98,691주를 매입했고 ARKK 펀드는 무려 280,192주를 매입했다.
최근 종가인 32.34달러를 감안할 때, 이번 매입 거래의 총 가치는 약 1,220만 달러에 달한다. 이러한 움직임은 월요일에 템퍼스 AI 주가가 13.81% 하락한 가운데 나온 것이다.
<h3>기타 주요 거래</h3>
<figure class="wp-block-table">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>회사</td>
<td>ETF</td>
<td>거래</td>
<td>주식 수</td>
<td>종가</td>
<td>대략적 가치</td>
</tr>
<tr>
<td>베라사이트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>)</td>
<td>ARK Genomic Revolution</td>
<td>매도</td>
<td>37,358</td>
<td>$42.78</td>
<td>$160만</td>
</tr>
<tr>
<td>어댑티브 바이오테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>)</td>
<td>ARK Genomic Revolution</td>
<td>매도</td>
<td>76,522</td>
<td>$6.46</td>
<td>$494,332</td>
</tr>
<tr>
<td>케어Dx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>)</td>
<td>ARK Genomic Revolution</td>
<td>매도</td>
<td>65,550</td>
<td>$25.07</td>
<td>$160만</td>
</tr>
</tbody>
</table>
</figure>
2025년 1월 13일 기준 종가
이미지 제공: Benzinga YouTube 및 Unsplash
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며 <a href="https://www.benzinga.com/author/Rounak-Jain" target="_blank" rel="noreferrer noopener">Rounak Jain</a>이 편집했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

아크 인베스트의 CEO인 캐시 우드는 인공지능, 유전자 염기서열(시퀀싱) 분석, 유전자 편집 기술의 교차점에서 전례 없는 잠재력을 발견하고 바이오 분야에 투자를 강화하고 있다.
무슨 일 있었나: 캐시 우드의 열정은 의료와 신약 개발에 혁명을 일으킬 수 있는 혁신적인 기술 융합에 집중되어 있다.
그는 이 분야에 대해 솔직하게 이야기하면서 특히 크리스퍼 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), 빔 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) 같은 회사에서 유전자 치료의 괄목할 만한 발전이 이루어지고 있다고 강조했다.
가장 눈에 띄는 사례는 최근 크리스퍼 테라퓨틱스가 겸상 적혈구 질환 치료 분야에서 거둔 획기적인 성과다. 우드는 이전에는 연간 12~20회 수혈을 받아야 했던 환자들이 이제 그런 수혈을 받지 않아도 될 수 있게 되었다고 언급했다.
이러한 전략은 치료의 혁신을 넘어 신약 개발 자체로 확장횐다. 우드는 리커션 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>)와 같은 회사가 인공지능을 활용하여 임상시험 실패율을 획기적으로 줄이고 신약 개발 일정을 앞당기고 있다고 강조했다.
그러나 이러한 혁신적인 기업들의 시장 성과는 좀 더 복잡한 이야기를 담고 있다. 올해 들어 이들 주식은 상당한 변동성을 보였다. <a href="//www.benzinga.com/pro/"" target="_blank" rel="noopener">벤징가 프로 데이터</a>에 따르면 연초 대비 크리스퍼 테라퓨틱스는 25.36% 하락, 인텔리아 테라퓨틱스는 52.21% 하락, 빔 테라퓨틱스는 3.04% 하락, 리커션 제약은 9.80% 하락했다.
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Which market sector excites <a href="https://twitter.com/CathieDWood?ref_src=twsrc%5Etfw">@CathieDWood</a> the most and why? In <a href="https://twitter.com/hashtag/askARK?src=hash&amp;ref_src=twsrc%5Etfw">#askARK</a>, she shares her growing enthusiasm for the biologics space.
Have more questions for Cathie? Share them in the comments. <a href="https://t.co/WjilZChce6">pic.twitter.com/WjilZChce6</a>
&mdash; ARK Invest (@ARKInvest) <a href="https://twitter.com/ARKInvest/status/1861431767506268404?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/stocks/%EC%BA%90%EC%8B%9C-%EC%9A%B0%EB%93%9C%EC%9D%98-%EC%95%84%ED%81%AC-%EC%9D%B8%EB%B2%A0%EC%8A%A4%ED%8A%B8-%ED%85%8C%EC%8A%AC%EB%9D%BC-%EC%A3%BC%EC%8B%9D-1800%EB%A7%8C-%EB%8B%AC%EB%9F%AC-%EC%83%81/" target="_blank" rel="noopener">캐시 우드의 아크 인베스트, 테슬라 주식 1,800만 달러 상당 매각</a>
왜 중요한가: 바이오 분야에 대한 아크 인베스트의 노력은 11억 7,900만 달러의 순자산을 관리하는 Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)를 통해 분명하게 드러난다. 이 펀드의 성과는 2020년 최고 180.50%에서 2022년 최저 -53.94%에 이르는 연간 수익률로 해당 섹터의 변동성을 반영하고 있다.
이 ETF의 현재 상위 보유 종목은 혁신적인 바이오 기술에 대한 캐시 우드의 전략적 초점을 강조한다. 트위스트 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>)가 8.90%의 비중으로 포트폴리오를 이끌고 있으며, 크리스퍼 테라퓨틱스가 7.88%, 리커션 파마슈티컬스가 6.17%로 그 뒤를 잇고 있다. 그 밖의 주요 투자 기업으로는 케어DX(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), 베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), 어댑티브 바이오테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) 등이 있으며, 이들은 게놈 및 생물학적 혁신에 대한 다양한 접근 방식을 대표한다.
캐시 우드는 AI, 시퀀싱 기술, 유전자 편집의 전례 없는 융합 덕분에 향후 5년 동안 바이오 분야에서 4,000억 달러의 시장 기회가 있을 것으로 전망한다.
이미지 출처: Ark Invest
면책 조항: 이 콘텐츠는 부분적으로 AI 도구의 도움을 받아 생성되었으며, Benzinga 편집자가 검토 후 게시했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

다음은 지난주 큰 폭의 상승세를 보인 7개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요?
<ol>
<li>루멘 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>)의 주가는 회사가 <a href="https://www.benzinga.com//node/40204727" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">2분기 매출 결과</a>를 보고한 후 113.82% 급등했다. 여러 분석가가 주식의 <a href="https://www.benzinga.com//node/40221474" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 가격</a>을 상향 조정했다.</li>
<li>업스타트 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>)가 <a href="https://www.benzinga.com//node/40227720" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">강한 2분기 실적을 발표</a>한 후 주가는 73.65% 급등했다. 많은 분석가들은 주식의 <a href="https://www.benzinga.com//node/40229270" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 가격</a>을 상향 조정했다.</li>
<li>ADMA 바이오로직스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>)의 주가는 예상보다 나은 2분기 재무 결과를 보고하면서 지난주 52.58% 상승했다.</li>
<li>스위트그린(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>)이 <a href="https://www.benzinga.com//node/40284819" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 나은 2분기 재무 실적</a>을 보고하고 강력한 FY24 수익 전망을 발표한 후 가 주가는 47.35% 상승했다. 몇몇 분석가들은 회사의 <a class="ticker" title="분기 재무 결과를 발표한 이후 47.35% 상승했으며, 이에 더해 24회계연도 1년간 좋은 수익 전망을 발표하였습니다. 몇몇 애널리스트들이 &lt;a href=" href="https://www.benzinga.com//node/40284819">목표 주가</a>를 높였다.</li>
<li>베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>)가 <a href="https://www.benzinga.com//node/40229725" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">예상보다 나은 2분기 재무 실적</a>을 발표한 후 주가는 46.57% 상승했다.</li>
<li>클리어 시큐어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>)가 2분기 재무 결과를 보고하고 예상보다 높은 3분기 <a href="https://www.benzinga.com//node/40181525" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">매출 지침</a>을 발표한 후 주가는 38.83% 증가했다.</li>
<li>코어 사이언티픽(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>)의 주가는 코어위브(CoreWeave)가 추가 <a href="https://www.benzinga.com//node/40194866" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">계약 옵션</a>을 행사했다고 발표한 뒤 38.37% 상승했다.</li>
</ol>
다른 뉴스도 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%87%bc%ed%94%bc%ed%8c%8c%ec%9d%b4-%eb%b0%8f-%ed%8c%94%eb%9e%80%ed%8b%b0%ec%96%b4%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%97%ac%ec%a4%80-10/" target="_blank" rel="noopener">쇼피파이 및 팔란티어는 지난주 최고 성과를 보여준 10개 대형주 중 일부 (8월 4일-8월 10일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%ec%9b%8c%eb%84%88-%eb%b8%8c%eb%9d%bc%eb%8d%94%ec%8a%a4-%eb%b0%8f-%eb%a7%a5%ec%bc%80%ec%8a%a8%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4/" target="_blank" rel="noopener">워너 브라더스 및 맥케슨은 지난주 최악의 성과를 보인 10개 대형주 중 일부 (8월 4일-8월 10일)</a></li>
</ul>
사진 제공: Lumen
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

월요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 로빈후드 마켓(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>)의 지분을 줄이는 중요한 조치를 취했다. 이 결정은 시장 변동 기간 중에 이루어졌으며 이 투자 회사가 자체 포트폴리오를 조정하는 최근 추세를 따랐다.
로빈후드(HOOD) 매매:
로빈후드에서 포지션을 축소하기로 한 아크 인베스트의 결정은 세 가지 ETF를 통해 실행되었다. ARK Fintech Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>)는 31,827주를 매각했고, ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 ARK Next Generation Internet ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 각각 215,675주와 76,299주를 매각했다. 월요일 로빈후드의 종가 23.42달러를 기준으로 판매된 주식의 총 가치는 약 760만 달러이다.
로빈후드 주식의 변동성은 <a href="https://www.benzinga.com/news/24/06/39234943/whats-going-on-with-robinhood-stock" target="_blank" rel="noopener">밈 주식 열기가 부활</a>하는 가운데 발생했다. 최근 로빈후드의 CEO 블래디미어 테네브는 게임스탑에 투자한 것으로 유명한 로어링 키티(Roaring Kitty)이라고도 알려진 키스 길(Keith Gill)의 예정된 라이브 스트리밍으로 인한 트래픽 유입을 회사가 처리할 준비가 되었다고 발표했다. 이 회사는 또한 최근 <a href="https://www.benzinga.com/news/24/05/39047461/robinhood-markets-stock-jumps-on-1b-buyback-whats-going-on">10억 달러 규모의 자사주 매입</a>을 발표했는데, 이는 주가 상승 추세에 기여했다.
특히 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)과 이더리움(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) 등 주요 코인들이 적자로 거래되면서 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39262872/bitcoin-ethereum-dogecoin-remain-choppy-analyst-forecasts-2x-10x-increase-for-king-crypto-" target="_blank" rel="noopener">고르지 못한 암호화폐 시장</a>을 배경으로 거래가 성사됐다.
다른 중요한 거래:
<ul>
<li>이그젝트 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>): ARKG 및 ARKK를 통해 주식 매도.</li>
<li>아크투러스 테라퓨틱스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>): ARKG를 통해 주식 매입.</li>
<li>텔라닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>): ARKG를 통해 주식 매도.</li>
<li>인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>): ARKG 및 ARKK를 통해 주식 매입.</li>
<li>버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>): ARKG 및 ARKK를 통해 주식 매도. 베라사이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>): ARKG 및 ARKK를 통해 5,804주 매입.</li>
</ul>
다음 읽어보기: <a href="https://www.benzinga.com/markets/equities/24/06/39246807/investor-naval-ravikant-threatens-to-sell-all-tesla-holdings-if-ceo-musks-pay-plan-is-rejected-b?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">CEO 일자리 대안에 대한 투자자의 협상</a>
이 이야기는 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>의 편집을 거쳐 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 제작되었습니다.

Comments

Veracyte

뉴스

에 대한 최신 뉴스 Veracyte (NASDAQ:VCYT) 주식

화요일, 1월 14, 2025

수요일, 11월 27, 2024

일요일, 8월 11, 2024

화요일, 6월 11, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌